|Status: One Wales interim decision|
Using the starting and stopping criteria, vedolizumab (Entyvio®) can be made available within NHS Wales for the treatment of inflammatory bowel disease in children and young people aged 6 to 17 years: for ulcerative colitis following loss of response or non-response to anti-TNF treatment; for Crohn’s disease following loss of response or non-response to anti-TNF treatment and ustekinumab.
The risks and benefits of the off-label use of vedolizumab (Entyvio®) for this indication should be clearly stated and discussed with the patient to allow informed consent.
Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.
This advice will be reviewed after 12 months or earlier if new evidence becomes available.
|Medicine name||vedolizumab (Entyvio®)|
Treatment of inflammatory bowel disease in children and young people aged 6 to 17 years
|Company||Takeda UK Ltd|
|BNF chapter||Gastro-intestinal system|
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||02/03/2023|